H-GVY^DGR^EHTV-OH

Ref. 3D-PP47282

Produktinformation

• Name: H-GVY^DGR^EHTV-OH

Beschreibung

Peptide H-GVY^DGR^EHTV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-GVY^DGR^EHTV-OH include the following: A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes Y Zhang , V Stroobant, V Russo, T Boon - Tissue , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-0039.2002.600503.x Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes T Ninkovic, L Kinarsky, K Engelmann, V Pisarev - Molecular , 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589008007001 New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells T Kobayashi, C Lonchay, D Colau, N Demotte - Tissue , 2003 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-0039.2003.00123.x Large-scale molecular dynamics simulations of HLA-A*0201 complexed with a tumor-specific antigenic peptide: Can the alpha3 and beta2m domains be neglected? S Wan , P Coveney , DR Flower - Journal of computational , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/jcc.20100 High-resolution structure of HLA-A∗ 0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene RC Hillig, PG Coulie , V Stroobant, W Saenger - Journal of Molecular , 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0022283601948168 Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy PC Simister, EC Border , JF Vieira - for Immunotherapy of , 2022 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295655/ Theoretical Dynamics and Energetics of HLA-A2/SLYNTVATL Interaction O Olaposi, H Tsuyoshi - American Journal of Bioinformatics Research, 2015 - academia.eduhttps://www.academia.edu/download/70861651/10.5923.j.bioinformatics.20150501.01.pdf A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes MT Duffour, P Chaux, C Lurquin - European journal of , 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1521-4141(199910)29:10%3C3329::AID-IMMU3329%3E3.0.CO;2-7 A library of cancer testis specific T cell receptors for T cell receptor gene therapy MAJ de Rooij, DFG Remst, DM van der Steen - Molecular Therapy , 2023 - cell.comhttps://www.cell.com/molecular-therapy-family/oncology/fulltext/S2372-7705(22)00142-5 de, Remst, DFG, Steen, DM an der, Wouters M Rooi - K., Hagedoorn, RS, Kester, MGD , 2023 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A3616927/download Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based K Davari, T Holland, L Prassmayer - for Immunotherapy of , 2021 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996660/ Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy JP Sanderson , DJ Crowley, GE Wiedermann - , 2020 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2019.1682381 The physiological interactome of TCR-like antibody therapeutics in human tissues E Marrer-Berger, A Nicastri, A Augustin - Nature , 2024 - nature.comhttps://www.nature.com/articles/s41467-024-47062-5 A de-risking experimental framework defines the physiological interactome of TCR-based therapeutics in human tissues E Marrer-Berger, A Nicastri , A Augustin, V Pulko - 2022 - researchsquare.comhttps://www.researchsquare.com/article/rs-1828302/latest

• Marke: Biosynth